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1. Introduction
Salinomycin is a carboxylic polyether ionophore which was isolated from the culture super‐
natant of the bacterium Streptomyces albus in 1974 [1]. Structurally, it is composed of a penta‐
cyclic molecule with a unique tricyclic spiroketal ring system and a unsaturated six-
membered ring (Fig. 1). Its lipophilic property enables salinomycin to act in cytoplasmic and
mitochondrial membranes as an ionophore with a strong preference for potassium. There‐
fore, it promotes cellular and mitochondrial potassium efflux and inhibits mitochondrial ox‐
idative phosphorylation [2, 3].
Salinomycin exhibits a broad antimicrobial spectrum against gram-positive bacteria includ‐
ing mycobacteria, Bacillus subtilis, Staphylococcus aureus and some filamentous fungi, but not
against gram-negative bacteria and yeast [1]. Moreover, salinomycin has been shown to kill
protozoan parasites, such as Plasmodium falciparum and Eimera spp., that cause severe cocci‐
diosis in the livestock and poultry industries. Owing to its anti-parasite properties, salino‐
mycin has been used to control coccidiosis in parasite-infected chickens and cows [4, 5].
More recently, the anticancer property of salinomycin has been recognized based on its abil‐
ity to induce apoptosis and cause growth inhibition in diverse types of apoptosis- and che‐
motherapeutic-resistant cancer cells [6]. Salinomycin-mediated apoptosis in these cells is
independent of known mediators of the cell death signal pathway, such as the p53 tumor
suppressor protein, the 26S proteasome and the CD95/DC95 ligand system. This drug also
triggers apoptosis by overcoming ATP-Binding Cassette (ABC) transporter-mediated multi‐
drug resistance, as was observed in the case of KG-1a human leukemia cells [7, 8]. Salinomy‐
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cin caused massive tumor cell apoptosis and associated regression of breast tumor growth
and metastasis in vivo in a mouse xenograft tumor model [9]. In fact, in high-throughput
screening of ~16,000 small molecule chemicals, breast cancer stem cells (CSCs) were found to
be inhibited selectively by salinomycin [9]. CSCs are a subpopulation of cells within the tu‐
mor mass that are thought to account for cancer recurrence by virtue of their refractivity to
cytotoxic cancer treatment agents such as radiation and a wide variety of chemotherapeutic
agents. Susceptibility of CSCs to salinomycin bolsters the possibility that this drug may tar‐
get treatment-resistant advanced human cancers. Delineation of the mechanism(s) that un‐
derlies cancer cell apoptosis by salinomycin is needed in order to rigorously evaluate the
potential of this drug as a novel cancer therapeutic.
Figure 1. Structural formula of salinomycin. It has a molecular mass of 751 Da and a molecular formula of C42H70O11.
Apoptosis is a regulated cell death process that requires the cascaded activation and execu‐
tion of a series of regulatory molecules and cysteine-aspartic proteases, known as caspases
[10]. Stress agents, such as reactive oxygen species (ROS), ultraviolet radiation, viral infec‐
tions, and anticancer agents are well-characterized apoptosis triggers. Mitochondria are the
primary site of origin for the initiating signals of apoptosis, although a death receptor-de‐
pendent extramitochondrial apoptotic pathway also exists. Mitochondrially originated
apoptotic signals include a change in the electron transport system, loss of mitochondrial
membrane potential (MMP, ΔΨm), failure of Ca2+ flux homeostasis, generation of ROS, and
release of caspase activators. Early apoptosis is invariantly marked by a breakdown in the
MMP, which precedes DNA fragmentation in all cell types and under all types of apoptotic
stimuli [11]. Production of endogenous ROS as mitochondrial byproducts of respiration is
tightly controlled by MMP. Disruption in the ROS homeostasis plays a critical role in the
regulation of mitochondrial dysfunction and apoptotic events [12].
Prostate cancer initially responds to androgen deprivation, which is a standard-of-care ther‐
apy when the androgen-dependent malignant cells meet with apoptotic death in an environ‐
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ment of low, castrate-level circulating androgens. Relapse, however, is a common
occurrence at which point the recurrent cancer cells are castration resistant and have the
ability to progress on chemotherapeutics to become completely therapy resistant [13-15].
In this chapter, we describe our recent findings that salinomycin induces apoptosis of pros‐
tate cancer cells by elevating oxidative stress through intracellular ROS production, which
leads to the disruption of mitochondrial function and subsequent release of cytochrome c to
the cytosol, activation of caspase-3, and cleavage of PARP-1 in androgen-independent, che‐
motherapeutic-refractive PC-3 human prostate cancer cells [16].
2. Salinomycin in human prostate cancer cells
Prostate cancer is the most frequently diagnosed cancer and the second leading cause of can‐
cer death among men in the United States. Considerable progress has been made in the ear‐
ly detection and treatment of prostate cancer over the last two decades. Nevertheless,
mortality from prostate cancer remains a significant health care problem [17]. Androgen
deprivation therapy is increasingly becoming a central component in the management of
prostate cancer. Although initially effective, patients acquire resistance and eventually de‐
velop metastatic castration-resistant prostate cancer (CRPC) [18-20]. For treatment in pa‐
tients with CRPC, chemotherapy with docetaxel represents the standard first-line treatment.
However, in order to prolong overall survival time after treatment with docetaxel, develop‐
ment of novel therapeutic strategies is essential.
2.1. Salinomycin reduced viability of prostate cancer cells at a lower dose than non-
malignant prostate epithelial cells
Our recent study has revealed that salinomycin induces apoptosis in human prostate cancer
cells by accumulated reactive oxygen species and mitochondrial membrane depolarization
[20]. Using androgen-independent PC-3 and DU-145, the androgen-dependent LNCaP pros‐
tate cancer cells and non-malignant RWPE-1 prostate epithelial cells, we examined the ef‐
fects of salinomycin on the viability of prostate cancer cells. When the cells were treated
with increasing concentrations of salinomycin for different time periods, the viability of
prostate cancer cells were reduced in a dose- and time-dependent manner (Fig. 2A, 2B and
2C). By comparison, RWPE-1 cells were relatively less sensitive to salinomycin, since at 0.15
μM concentration, the drug did not significantly inhibit viable cell number (Fig. 2D), unlike
the all three cancer cells, which showed significant drop in viability in MTT assay. To some
extent, differential sensitivity to the drug was also seen for LNCaP vs PC3 and DU-145 cells,
since at 1.33 μM of the drug, LNCaP cells manifested a stronger inhibition -- viability re‐
duced to ~55%, 38%, 35% and 22% (after 12 h, 24 h, 36 h and 48 h, respectively), whereas
>50% of PC-3 and DU-145 cells remained viable after 36 h treatment of the drug (at 1.33
μM), and even at 48 h, >30% of PC-3 cells and >50% of DU-145 cells remained viable (Fig. 2B
vs. Figs 2A & 2C). At 0.15 μM salinomycin, the three cell lines showed approximately simi‐
lar sensitivity to the drug. To summarize, these results indicate that the chemo-resistance of
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the hormone-independent cancer cells to salinomycin is higher than that of the hormone-de‐
pendent cells, and compared to the cancer cells, non-malignant prostate epithelial cells (such
as RWPE-1) are relatively more resistant to salinomycin. We next focused on the PC-3 cell
model to investigate the molecular events associated with the salinomycin-induced loss of
cell viability [20].
Figure 2. Salinomycin inhibited viability of prostate cancer cells. (A) PC-3 (B) LNCaP (C) DU-145 (D) RWPE-1 cells. 5 ×
104 cells/ml were treated with salinomycin (0.15–4.00 μM) at different time points (12 h, 24 h, 36 h and 48 h). Cell
viability was determined by MTT assay. Data are presented as mean ± SD (n = 3 in each group). #p<0.05, p<0.01,
*p<0.001 vs. the control group.
2.2. Salinomycin induced PC-3 cell apoptosis
To examine if the salinomycin effect is due to apoptosis, we examined PC-3 cells for the nu‐
clear morphology, annexin V staining and induction of various apoptosis-related molecular
events before and after salinomycin treatment [20]. Laser scanning confocal microscopy of
DAPI-stained PC-3 cells showed that in the absence of the drug, the nuclei were round and
homogeneous, whereas salinomycin treatment caused a reduction of cell volume, nuclear
Advances in Prostate Cancer364
condensation (a hallmark feature of apoptotic cells), and increased non-adherence of the
cells to the culture surface (Fig. 3A). Induction of apoptosis was rigorously substantiated by
examining the flow cytometry pattern of annexin V stained cells (Fig. 3B). Apoptotic cells
accounted for 27.13% and 34.61% of the cells in early apoptosis plus late apoptosis, and ne‐
crotic cells were 13.03% and 21.24% of total cells, in response to salinomycin treatment at
1.33 μM and 4.00 μM, respectively (Fig. 3B). Taken together, these results show that salino‐
mycin induced apoptotic cell death; at higher doses necrosis may also account for cell death.
Figure 3. Salinomycin induced apoptosis in PC-3 cells. (A) Morphological changes. After treatment with salinomycin
(1.33 and 4.00 μM) for 24 h and 48 h, nuclear fragmentation was observed by laser scanning confocal microscopy.
Magnification, at × 1,800. (B) Flow cytometric analysis of annexin V/propidium iodide (PI) staining. PC-3 cells were
treated with various concentrations of salinomycin for 48 h. The dual parameter dot plots combining annexin V and PI
show the viable cell population in the lower left quadrant (annexin V-PI-), apoptotic cells in the lower right quadrant
(annexin V+PI-) and the upper right quadrant (annexin V+PI+), and necrotic cells in the upper left quadrant (annexin V-PI
+). (C) Bax and Bcl-2 expression in total cell lysates, detected by western blotting. (D) Pro-caspase-3 and poly (ADP-
ribose) polymerase (PARP-1, cleaved and uncleaved) levels. (E) Caspase-3 activity, determined by a colorimetric assay
kit using the specific substrate Ac-DEVD-pNA. Data show mean ± SD (n = 3 in each group). #p<0.01 vs. the control
group.
Recently,  a similar study has been performed by Ketola et al.,  describing that salinomy‐
cin is capable of inhibiting the growth of prostate cancer cells, but not affecting non-ma‐
lignant prostate epithelial cells [21]. However, in contrast to our results that salinomycin
induces apoptosis in PC-3 cells, the authors were not able to detect caspase-3- and 7-medi‐
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ated apoptosis  in prostate  carcinoma cells,  VCaP and LNCaP,  by salinomycin treatment
(see below). This discrepancy is probably due to the different prostate cell lines were used
in each study.
2.3. Salinomycin differentially altered the levels of Bcl-2 family proteins and induced
caspase-3 activation and PARP-1 cleavage in PC-3 cells
In addition, we examined the expression of Bax and Bcl-2, the apoptosis and cell survival
related protein, respectively, and also cleavage of pro-caspase-3, and PARP-1 (a caspase-3
substrate) using western blotting [16]. Salinomycin increased Bax expression and decreased
Bcl-2 expression in a dose-dependent manner within total cell lysates (Fig. 3C). Furthermore,
declining pro-caspase-3 levels and increasing cleavage of PARP-1 were evident with increas‐
ingly higher salinomycin concentrations (Fig. 3D). Caspase-3 activity assay using an in vitro
colorimetric method further confirmed caspase-3 activation in the presence of salinomycin.
Treatment of PC-3 cells with the drug for 48 hr resulted in a dose-dependent increase of cas‐
pase-3 activity (Fig. 3E). Thus, salinomycin mediated a cascaded series of molecular events
that led to an attenuated level of Bcl-2, augmented level of the pro-apoptotic protein Bax,
and activation of the executer apoptosis enzyme caspase-3.
2.4. Intracellular production of ROS in PC-3 cells increased markedly after salinomycin
treatment
Cancer chemotherapy is  known to induce tumor cell  death in a  variety of  cell  types in
part  by  promoting  the  production  of  intracellular  ROS  [21].  In  order  to  demonstrate
whether ROS production is associated with salinomycin-induced apoptosis of PC-3 cells,
we assessed the state of ROS at various time points after salinomycin treatment by exam‐
ining  the  fluorescence  intensity  of  DCHF-DA-incubated  cells.  A  representative  fluores‐
cence pattern from flow cytometry (Fig. 4A, upper panel) shows that the intracellular ROS
level increased after 4 h of salinomycin treatment, and pretreatment of the cells with the
antioxidant  N-acetylcysteine  (NAC),  a  known quencher  of  ROS,  left  shifted the  fluores‐
cence  peak  closer  to  the  peak  generated  by  cells  with  no  treatment  or  NAC treatment
without subsequent exposure to salinomycin. The number of DCF-positive cells increased
as early as 15 min following exposure to 1.33 μM salinomycin, and the peak production of
ROS was after 4 h incubation of the drug (Fig.  4A, lower panel).  As expected,  pretreat‐
ment  of  the  cells  with  NAC  reduced  the  number  of  DCF-positive  cells.  NAC  also  in‐
creased the cell viability from 41.96% to 57.08% for 1.33 μM and from 25.4% to 41.21% for
4.00 μM of salinomycin (Fig. 4B).  Salinomycin-induced caspase-3 activation in PC-3 cells
was also inhibited by NAC (Fig. 4C).  These findings suggest that intracellular ROS pro‐
duction is closely linked to caspase-3 activation and to the viability of PC-3 cells [20]. Con‐
sistent  with  these  data,  similar  results  has  observed that  salinomycin  induces  oxidative
stress  in  VCaP  and  LNCaP  cells  detemined  by  the  expression  level  of  oxidative  stress
markers and intracellular level of ROS [22].
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Figure 4. Salinomycin mediated ROS-induced apoptosis. (A) The intracellular ROS level. Cells were treated with salino‐
mycin (1.33 μM) for indicated time periods with or without prior 1 h incubation with N-acetylcysteine (NAC; 10 mM).
The dichlorodihydrofluorescein (DCF) fluorescence intensity in the cells was detected by flow cytometry. (B) Cytotoxici‐
ty. Cells were treated with salinomycin for 48 h with or without pre-treatment for 1 h with NAC (10 mM). (C) Cas‐
pase-3 activity. Cells were treated with salinomycin for 48 h with or without NAC (10 mM, 1 h). Data are presented as
mean ± SD (n = 3 in each group). p<0.01, *p < 0.001 vs. the control group.
2.5. Salinomycin induced loss of mitochondrial membrane potential in PC-3 cells
ROS is known to be involved in specific aspects of mitochondrial dysfunctions such as open‐
ing of the mitochondrial permeability transition pore that causes depolarization of the mito‐
chondrial transmembrane potential (MMP; ΔΨm), release of apoptogenic factors and loss of
oxidative phosphorylation. Flow cytometry of DiOC6 fluorescence dye-labeled PC-3 cells
showed progressive left shift of fluorescence intensity, indicating reduction in MMP, after
treatment with 1.33 μM and 4.00 μM salinomycin (Fig. 5A, upper panel). Reduction in MMP
was also prevented in NAC-pretreated cells, as shown in the results of intracellular ROS lev‐
el (Fig. 5A, lower panel). These data suggest that dissipation of MMP in salinomycin-treated
PC-3 cells is dependent on intracellular ROS production [20].
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Figure 5. Salinomycin induced dysfunctions of mitochondrial membrane in PC-3 cells. (A) Mitochondrial membrane
potentials (MMP). Cells were treated with salinomycin (1.33 and 4.00 μM) for 48 h in the presence or absence of 1 h
pre-incubation with NAC (10 mM). MMP changes were determined from DiOC6 fluorescence, measured by flow cy‐
tometry analysis. Data are presented as mean ± SD (n = 3 in each group). p<0.01, *p<0.001 vs. the control group. (B)
Bax translocation and release of cytochrome c. The levels of Bax and cytochrome c in the cytosol fraction and mito‐
chondrial fraction were determined by western blotting. (C) Mitochondrial Bax translocation. Confocal microscopic
images were observed by using the mitochondria staining dye Mitotracker Red CMXROS and anti-Bax antibody. Mag‐
nification, at × 1,800.
2.6. Salinomycin promoted Bax translocation to mitochondria and cytosolic release of
cytochrome c
Participation of mitochondrial components in salinomycin-induced apoptosis was deter‐
mined by assessing the subcellular localization of Bax and cytochrome c before and after sal‐
inomycin treatment. The drug triggered Bax translocation onto the mitochondrial
membrane (Fig. 5B, upper panel) and mitochondrial cytochrome c release into the cytosol
(Fig. 5B, lower panel), revealed from western blot assay. Bax translocation to mitochondria
was visually confirmed by confocal microscopy (Fig. 5C), which showed a greatly enhanced
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staining for Bax in the mitochondrial compartment after treatment with salinomycin (1.33
μM) for 24 h or 48 h. These data suggest that salinomycin plays a pivotal role in the mito‐
chondrial uptake of Bax and concomitant release of cytochrome c [20].
3. Salinomycin in human cancer stem cells and cancer cells
Anticancer activity of salinomycin was first described by Gupta et al. [9]. They developed an
automated high-throughput screening method to discover compounds showing selective
toxicity for breast CSCs. Among more than 16,000 small molecule chemicals, only one com‐
pound, salinomycin, was identified as a selective inhibitor of breast CSCs, and salinomycin
pretreatment resulted in a >100-fold decrease in tumor-seeding ability relative to paclitaxel,
a commonly used breast cancer chemotherapeutic drug [23], indicating that CSCs within
breast cancer cell populations are resistant to paclitaxel but sensitive to treatment with sali‐
nomycin [9].
Salinomycin has been validated for its anticancer effects on CD4+ T-cell leukemia cells from
from the peripheral blood of a patient with acute T-cell leukemia [7]. While salinomycin
failed to induce apoptosis in normal CD4+ T cells, various human leukemia and lymphoma
cells undergo apoptosis by salinomycin treatment. Interestingly, salinomycin induces apop‐
tosis selectively in human cancer cells that exhibit resistance to apoptosis by lacking p53 ex‐
pression and anticancer agents by overexpression of Bcl-2, P-glycoprotein or 26S
proteasomes with enhanced proteolytic activity [7, 24]. Although the exact mechanism of
salinomycin-induced apoptosis is unknown, this study highlights that salinomycin activates
a distinct apoptotic pathway in cancer cells that is not accompanied by cell cycle arrest and
that is independent of p53, caspase activation, the CD95/CD95L system and the 26S protea‐
some [7]. In addition, a new study demonstrated that salinomycin massively induces apop‐
tosis in human leukemia stem cell-like cells which is expressing various ABC transporters
conferring resistance to a broad spectrum of chemotherapeutic drugs [8].
In order to identify and improve conditions for increasing sensitivity of cancer cells to dox‐
orubicin (DOX) or etoposide (ETO), various human cancer cells were co-treated with salino‐
mycin and DOX- or ETO-pretreated cells [25]. The authors has shown that salinomycin is
able to sensitize cancer cells to the effects of DOX or ETO. Intriguingly, they also has demon‐
strated for the first time that salinomycin sensitizes cancer cells with two different path‐
ways, which mediated by increased DNA damage and reduced p21 protein levels through
increased proteasome activity [25]. These findings suggest that salinomycin may be used for
combination chemotherapy with DOX or ETO to reduce the viability of cancer cells.
The in vitro effects of salinomycin on aldehyde dehydrogenase (ALDH)-positive lung cancer
cell line A549 has been observed [26]. ALDH is highly expressed in several tumor types in‐
cluding brain, breast, liver, colon, pancreas and lung [27], and ALDH positive cells from
these tumors has been shown to enrich for tumor initiating cells with increased proliferation
rate, migration and adhesion ability, and more recently with metastatic potential [28]. Treat‐
ment of salinomycin not only ruptured the lung cancer tumorospheres from ALDH positive
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A549 lung cells but also reduced the expression of stem cell markers such as OCT-4,
NANOG and SOX2 [26]. This study suggests that salinomycin may be a promising agent for
lung cancer chemotherapy.
Anticancer effects of salinomycin on cancer stem-like cells in human colorectal cancers
(CRC) have been described [29]. CD133+ cell subpopulations within CRC have been identi‐
fied as cancer stem-like cells, which are resistant to many current cancer therapies [30]. Sali‐
nomycin reduced the proportion of CRC CD133+ cell subpopulations and upregulated
expression of E-cadherin in CRC cells, suggesting that salinomycin may induce the mesen‐
chymal-epithelial transition in the CRC cells. Furthermore, treatment of salinomycin re‐
duced clonogenicity and mobility of the CRC cells [29].
A recent study has shown that salinomycin is active against human squamous cell carcino‐
mas (SCCs) [31]. Based on the expression level of surface E-cadherin, SCCs can be classified
into mesenchymal-like (Ecad-lo) cells and epithelial-like (Ecad-hi) cells, and upon down-reg‐
ulating surface expression of E-cadherin, SCCs acquire mesenchymal-like phenotypes in‐
creasing resistance to both cytotoxic and targeted agents [32]. In contrast to cisplatin which
selectively depleted Ecad-hi cells, salinomycin displayed comparable efficacy against both
Ecad-hi and Ecad-lo cells [31].
More recently, the biochemical mechanism of anticancer effects of salinomycin has been
demonstrated in chronic lymphocytic leukemia cells and osteosarcoma cells [33, 34]. As an
inhibitor of Wnt/β-catenin signaling which plays a crucial role in embryonic development
and cancer [35-37], salinomycin has been shown to block the phosphorylation of the Wnt
coreceptor lipoprotein receptor related protein 6 (LRP6) and induce its degradation [33, 34].
These findings suggest that the anticancer properties of salinomycin may be mediated by
Wnt inhibition, and targeting Wnt receptors LRP6 could represent a novel therapeutic treat‐
ment for cancers [37].
Using human ovarian cancer cell line OV2008, Dong et al. [38] very recently has reported
that salinomycin inhibits the growth of ovarian cancer cells by inducing apoptosis in vitro
and in vivo. To examine the signal pathway involved in salinomycin-induced growth inhibi‐
tory effect and apoptosis in OV2008 cells, the authors determined the phosphorylation of
p38 MAPK which is implicated in cancer cell apoptosis and is induced by several chemo‐
therapeutic drugs [39]. They observed that salinomycin treatment to OV2008 cells increases
in the phosphorylation of p38 MAPK in a time-dependent and a concentration-dependent
mode, suggesting that the activation of p38 MAPK appears to contribute to the proapoptotic
effect of salinomycin in OV2008 cells [38].
4. Conclusion
The pharmacologic action of salinomycin has garnered increased attention in recent years in
view of its potential as a new cancer chemotherapeutic based on its activity as a selective
inhibitor of breast cancer stem cells. Salinomycin treatment also reduced formation of meta‐
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static nodules by CSCs [6, 40]. Since CSCs are inert to all current cancer therapy interven‐
tions, they are likely to drive tumor recurrence and progression. The absence of androgen
receptor expression in the putative CSCs in prostate cancer suggests that targeting of the an‐
drogen receptor pathway will not yield lasting therapy for advanced prostate cancer. A re‐
cent finding that salinomycin is detrimental to the viability of androgen-dependent and
androgen-independent prostate cancer cells due to the onset of apoptosis hints at the possi‐
bility that this drug or more likely, a significantly less cytotoxic derivative of this drug activ‐
ity, may have clinical utility as part of a future treatment strategy for advanced prostate
cancer [20].
Our present study shows 1) salinomycin decreased viability of the androgen-dependent
LNCaP and androgen-independent PC-3 and DU-145 prostate cancer cells in MTT assay in a
time- and dose-dependent manner. The non-malignant RWPE-1 prostate epithelial cells
were resistant to the drug-induced lethality at a lower salinomycin dose, which was still ef‐
fective in inhibiting LNCaP, PC-3 and DU-145 cells; 2) Early and late apoptosis and necrosis
in salinomycin-treated PC-3 cells was revealed from the nuclear morphology of DAPI-
stained cells and from flow cytometry of annexin V-labeled cells; 3) Biochemical evidence of
apoptosis came from the results that salinomycin activated caspase-3, induced cleavage of
PARP-1 and caused a dose-dependent decreased expression of the survival protein Bcl-2
and increased expression of the pro-apoptotic protein Bax; 4) Bax was translocated to the
mitochondria and cytochrome c was released into the cytosol of salinomycin-treated PC-3
cells, in agreement with the known coordinated events in the apoptosis pathway in which
translocated Bax forms a transmembrane pore across the outer mitochondrial membrane,
which in turn helps the cytosolic release of cytochrome c; 5) Finally, new evidence presented
here shows that salinomycin promotes escalation of intracellular ROS levels which is accom‐
panied by decreased mitochondrial membrane potential and increased caspase-3 activity of
PC-3 cells and these effects of salinomycin were prevented by pretreatment of the cells with
the antioxidant NAC (Fig. 6).
Previously it was reported that cancer chemopreventive agents induce apoptosis in part
through ROS generation and disruption of redox homeostasis [41]. It is also known that the
pro-apoptotic signal(s) emanating from accumulated ROS triggers the mitochondrial release
of caspase-activating proteins, such as cytochrome c, apoptosis inducting factor (AIF) and
Smac/DIABLO to the cytosol [42]. ROS shows secondary messenger function because of its
ability to influence MMP and mitochondrial function and to induce intracellular Ca2+ flux
and eventual activation of the caspase cascade [43]. Although our results provide clear evi‐
dence of salinomycin-induced ROS generation, mitochondrial membrane depolarization
and augmentation of caspase-3 activity in PC-3 cells, we did not detect any change in the
intracellular Ca2+ level [20].
The mechanistic implication of our data is that salimomycin-mediated ROS production, in‐
itiated upstream of  mitochondrial  dysfunction,  is  a  determining event  that  commits  the
cancer cells to apoptotic death subsequent to the loss of MMP, cytosolic release of cyto‐
chrome  c  and  activation  of  the  caspase  zymogen  cascade.  The  link  between  ROS  and
apoptosis in salinomycin-exposed cells was also evident from the inhibition of apoptosis
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in NAC-pretreated PC-3 cells [20]. The NAC inhibition hints at the possibility that the ex‐
tent  of  salinomycin-induced cytotoxicity in a therapeutic  setting may be controlled with
the intermittent use of an antioxidant in the therapeutic regimen of prostate cancer treat‐
ment.  In  contrast,  however,  a  recent  study has  shown that  salinomycin inhibits  growth
and migration of prostate cancer cell lines, VCaP and LNCaP, by reducing the expression
of some prostate cancer oncogenes such as MYC, AR and ERG, inducing oxidative stress,
decreasing  the  antioxidative  capacity  and the  proportion  of  CSCs,  but  not  by  inducing
apoptosis  [21].  Nevertheless,  these  studies  suggest  that  salinomycin  may  have  multiple
mechanisms to inhibit prostate cancer cell growth.
Figure 6. Schematic representation of salinomycin-induced apoptosis in human prostate cancer cells.
Future extension of the studies will constitute evaluating the anticancer efficacy of salino‐
mycin on human prostate cancer xenograft models and on patient-derived primary prostate
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tumor cells, and the investigation of a group of salinomycin derivatives which are more ef‐
fective and less toxic for humans is a challenge in the near future.
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